FDA OKs Expanded RSV Vaccine Use
The FDA expanded approval for GSK’s Arexvy RSV vaccine to include adults aged 18–49 at increased risk, a major update for family health. Previously, it was only for those 60 and older. The CDC estimates 21 million U.S. adults under 50 have at least one risk factor for severe RSV, and the virus was linked to as many as 350,000 hospitalizations and up to 23,000 deaths in a single recent season.
GSK's Arexvy is the first RSV vaccine approved for this expanded age group. The FDA's decision was based on trials showing the vaccine's ability to elicit an immune response in adults 18-49 with certain risk factors. These risk factors include chronic lung disease, asthma, diabetes, and heart conditions. The CDC still needs to recommend the vaccine for this group before it's widely administered. This expanded approval offers a new preventative measure for younger adults at higher risk, potentially reducing severe illness and hospitalization. GSK expects the vaccine to be available for this expanded age group in time for the 2026-2027 RSV season. The company is working with the CDC and other public health organizations to raise awareness. Broader availability could significantly impact public health strategies for managing RSV.
